May 8th 9am MDT: Year-End Update Webcast with Live Q&A. Follow the link below to the Webcast replay: http://services.choruscall.com/links/resverlogix0800508.html
Upcoming Events
May 19, 2008: Rodman & Renshaw, Monte Carlo Monaco
About Resverlogix Corp.
We are a leading biotechnology company working toward the development of novel therapies for unmet medical markets. Our goal is to improve patients’ longevity and quality of life by becoming a leader in the research, development and commercialization of products for cardiovascular disease, cancer and fibrotic conditions.
Our Product Development
NexVas™ Plaque Regression (NexVas PR) is a technology platform for the development of drugs that increase ApoA-I to reduce the risk of cardiovascular diseases.
NexVas™ Vascular Inflammation (NexVas VI) is a discovery stage technology for the development of drugs that target molecular markers of inflammation.
NexVas™ Alzheimer's Disease (NexVas AD) is a discovery stage technology for the development of drugs that enhance ApoA-I for stabilization and regression of Beta Amyloid Plaque (AD).
ReVas™ is a research stage technology for the development of therapeutics to be used with medical devices for the treatment of cardiovascular diseases.
TGF-β Shield™ is a research stage therapeutic for the treatment of grievous proliferative diseases, such as cancer and fibrotic conditions.
May 19, 2008: Rodman & Renshaw, Monte Carlo Monaco
About Resverlogix Corp.
About Resverlogix Corp.
We are a leading biotechnology company working toward the development of novel therapies for unmet medical markets. Our goal is to improve patients’ longevity and quality of life by becoming a leader in the research, development and commercialization of products for cardiovascular disease, cancer and fibrotic conditions.
Our Product Development
NexVas™ Plaque Regression (NexVas PR) is a technology platform for the development of drugs that increase ApoA-I to reduce the risk of cardiovascular diseases.
NexVas™ Vascular Inflammation (NexVas VI) is a discovery stage technology for the development of drugs that target molecular markers of inflammation.
NexVas™ Alzheimer's Disease (NexVas AD) is a discovery stage technology for the development of drugs that enhance ApoA-I for stabilization and regression of Beta Amyloid Plaque (AD).
ReVas™ is a research stage technology for the development of therapeutics to be used with medical devices for the treatment of cardiovascular diseases.
TGF-β Shield™ is a research stage therapeutic for the treatment of grievous proliferative diseases, such as cancer and fibrotic conditions.
